ASTS
AST SpaceMobile, Inc.
ASTS has a slight edge over ZENA overall, supported by stronger fundamentals and lower modeled downside.
ZENA
ZenaTech, Inc.
ZENA offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
ZENA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Weak |
ZENA's revenue is currently healthy, but its profitability, cash flow and balance sheet are weak.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
ZENA PE Valuation
ZENA has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
ZENA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect ZENA's losses to shrink, with revenue growing.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS has the edge over ZENA on earnings, with more consistent year-over-year improvement.
ZENA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.41 | -$1.00 |
| Q1 2026 | -$1.34 | -$1.05 |
| Q4 2025 | -$0.93 | -$0.78 |
| Q3 2025 | -$0.62 | -$0.58 |
| Q2 2025 | -$0.41 | -$0.39 |
| Q1 2025 | -$0.29 | -$0.28 |
| Q4 2024 | -$0.15 | -$0.14 |
| Q3 2024 | -$0.04 | -$0.02 |
ZENA lost $1.41 per share over the past year, and its loss has widened in each of the last nine quarters.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over ZENA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
ZENA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $6.5M | +314% |
| Q1 2026 | $6M | +652% |
| Q4 2025 | $3.6M | +671% |
| Q3 2025 | $3.1M | +1225% |
| Q2 2025 | $1.6M | +504% |
| Q1 2025 | $798.4K | +92% |
| Q4 2024 | $473.4K | -4.4% |
| Q3 2024 | $230.5K | +23% |
ZENA's revenue has grown year over year for six quarters in a row: $7M last quarter, up 314% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -235% | -60 points |
| Q1 2026 | -257% | +6.8 points |
| Q4 2025 | -262% | +97 points |
| Q3 2025 | -101% | +61 points |
| Q2 2025 | -174% | -149 points |
| Q1 2025 | -263% | -269 points |
| Q4 2024 | -359% | -420 points |
| Q3 2024 | -162% | -131 points |
ZENA has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
ZENA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$18.9M | -$13.7M |
| Q1 2026 | -$14.9M | -$10.9M |
| Q4 2025 | -$14.2M | -$10M |
| Q3 2025 | -$5.9M | -$4.3M |
| Q2 2025 | -$5.2M | -$4.9M |
| Q1 2025 | -$4M | -$3.7M |
| Q4 2024 | -$4.2M | -$2.8M |
| Q3 2024 | -$1.6M | -679% |
ZENA has burned cash in almost every quarter: −$54M over the past year, against −$15M the year before.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has the edge over ZENA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
ZENA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +137% | +46.8M shares |
| 1 year | +156% | +49.3M shares |
| 3 years | +381% | +64.1M shares |
ZENA has 81M diluted shares, up 156% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
ZENA hasn't bought back shares in the past year.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ZENA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | 81.3x | High |
| Q2 2024 | 17.6x | High |
| Q1 2024 | 16.8x | High |
| Q4 2023 | 17.2x | High |
| Q3 2023 | 46.4x | High |
| Q2 2023 | 17.0x | High |
| Q1 2023 | 0.0x | Very low |
| Q4 2022 | 8.4x | High |
ZENA's net debt is more than 20 years of its operating earnings (EBITDA), up from more than 20 years a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
ZENA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 2.7 | Oversold |
ZENA's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
ZENA PE vs Technology Sector
ZENA has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has stronger trend alignment. ASTS is above 1 of 5 weekly averages versus ZENA above 0 of 4.
ZENA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.01 | 38% below |
| 20 week MA | $1.36 | 54% below |
| 50 week MA | $2.06 | 69% below |
| 100 week MA | $3.23 | 80% below |
ZENA is in a downtrend: it's below all four of its weekly moving averages, and 80% below its 100-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS has the edge over ZENA on returns for 2026, with the stronger performance.
ZENA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $3.91 | $8.48 | +117% |
| 2025 | $8.48 | $3.42 | -60% |
| 2026 YTD | $3.42 | $0.63 | -82% |
ZENA's yearly returns have swung widely, from +117% in 2024 to −60% in 2025. It's down 82% so far in 2026.